Interactions between triazoles and amphotericin B in treatment of disseminated murine infection by fusarium oxysporum

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 4, 2009, Pages 1705-1708

  Ruíz Cendoya, Mery ^a   Mariné, Marçal ^a   Rodriguez M ^a   Guarro, Josep ^a  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; POSACONAZOLE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FUNGUS; FUSARIOSIS; FUSARIUM OXYSPORUM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; THERAPY EFFECT;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; DRUG THERAPY, COMBINATION; FUSARIUM; MALE; MICE; MYCOSES; PYRIMIDINES; TRIAZOLES;

EID: 65649106220     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01606-08     Document Type: Article

References (21)

1. Alastruey-Izquierdo, A., M. Cuenca-Estrella, A. Monzón, E. Mellado, and J. L. Rodrfguez-Tudela. 2008. Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods. J. Antimicrob. Che-mother. 61:805-809.
2. Anaissie, E., Kantarjian, J. Ro, R. Hopfer, K. Rolston, V. Fainstein, and G. Bodey. 1988. The emerging role of Fusarium infections in patients with cancer. Medicine 67:77-83. (Pubitemid 18106362)
3. Azor, M., J. Gene, J. Cano, and J. Guarro. 2007. Universal in vitro antifungal resistance of genetic clades of the Fusarium solani species complex. Antimi-crob. Agents Chemother. 51:1500-1503. (Pubitemid 46586837)
4. Boutati, E., and E. J. Anaissie. 1997. Fusarium, a significant emerging patho-gen in patients with hematologic malignancy: ten years experience at a cancer center and implications for management. Blood 90:999-1008. (Pubitemid 27314133)
5. Clemons, K. V., M. Espíritu, R Parmar, and D. A. Stevens. 2005. Comparative efficacies of conventional amphotericin B, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in com-bination against experimental murine central nervous system aspergillosis. Antimicrob. Agents Chemother. 49:4867-4875. (Pubitemid 41778896)
6. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard-second edition. CLSI document M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Eliopoulos, G. M., and R. C. Moellering. 1991. Antimicrobial combinations, p. 432-492. In V. Lorian (ed.), Antibiotics in laboratory medicine, 3rd ed. The Williams & Wilkins Co., Baltimore, MD.
8. Guarro, J., I. Pujol, and E. Mayayo. 1999. In vitro and in vivo experimental activities of antifungal agents against Fusarium solani. Antimicrob. Agents Chemother. 43:1256-1257. (Pubitemid 29214756)
9. Ho, D. Y., J. D. Lee, F. Rosso, and J. G. Montoya. 2007. Treating dissemi-nated fusariosis: amphotericin B, voriconazole or both? Mycoses 50:227-231. (Pubitemid 46683972)
10. Johnson, M. D., C. MacDougall, L. Ostrosky-Zeichner, J. R Perfect, and J. H. Rex. 2004. Combination antifungal therapy. Antimicrob. Agents Che-mother. 48:693-715. (Pubitemid 38280314)
11. Lewis, R., H. Hogan, A. Howell, and A. Safdar. 2008. Progressive fusariosis: unpredictable posaconazole bioavailability, and feasibility of recombinant interferon-gamma plus granulocyte macrophage-colony stimulating factor for refractory disseminated infection. Leuk. Lymphoma 49:163-165.
12. Musa, M. O., A. Al Eisa, M. Halim, E. Sahovic, M. Gyger, N. Chaudhri, F. Al Mohareb, P. Seth, M. Aslam, and M. Aljurf. 2000. The spectrum of Fusarium infection in immunocompromised patients with haematological malignancies and in non-immunocompromised patients: a single institution experience over 10 years. Br. J. Haematol. 108:544-548. (Pubitemid 30196251)
13. Nucci, M., and E. Anaissie. 2007. Fusarium infections in immunocompro-mised patients. Clin. Microbiol. Rev. 20:695-704. (Pubitemid 47623773)
14. Ortoneda, M., J. Capilla, F. J. Pastor, I. Pujol, and J. Guarro. 2004. In vitro interactions of licensed and novel antifungal drugs against Fusarium spp. Diagn. Microbiol. Infect. Dis. 48:69-71. (Pubitemid 38167503)
15. Paugam, A. 2007. The latest data on posaconazole. Med. Mal. Infect. 37:71-76.
16. Perfect, J. R, K. A. Marr, T. J. Walsh, R. N. Greenberg, B. DuPont, J. de la Torre-Cisneros, G. Just-Niibling, H. T. Schlamm, I. Lutsar, A. Espinel-Ingroff, and E. Johnson. 2003. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin. Infect. Dis. 36:1122-1131. (Pubitemid 36549632)
17. Raad, I. L, R. Y. Hachem, R Herbrecht, J. R. Graybill, R. Hare, G. Corco-ran, and D. P. Kontoyiannis. 2006. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin. Infect. Dis. 42:1398-1403.
18. Rodriguez, C. A., J. Luján-Zilbermann, P. Woodard, M. Andreansky, and E. E. Adderson. 2003. Successful treatment of disseminated fusariosis. Bone Marrow Transplant. 31:411-412. (Pubitemid 36410690)
19. Rufz-Cendoya, M., M. Mariné, and J. Guarro. 2008. Combined therapy in treatment of murine infection by Fusarium solani. J. Antimicrob. Chemother. 62:543-546.
20. Sun, Q., L. Najvar, R Bocanegra, D. Loebenberg, and J. R. Graybill. 2002. In vivo activity of posaconazole against Mucor spp. in an immunosuppressed- mouse model. Antimicrob. Agents Chemother. 46:2310-2312. (Pubitemid 34665939)
21. Tortorano, A. M., A. Prigitano, G. Dho, M. C. Esposto, C. Gianni, A. Gran-cini, C. Ossi, and M. A. Viviani. 2008. Species distribution and in vitro antifungal susceptibility patterns of 75 clinical isolates of Fusarium spp. from northern Italy. Antimicrob. Agents Chemother. 52:2683-2685.